By Anne Tergesen
The Wall Street Journal
Originally published December 8, 2013
As the price of sequencing a person's entire DNA has tumbled from $1 billion a decade ago to a few thousand dollars today, many adults—and their physicians—are turning to genetic tests to better understand and manage their health.
The process, though, can be problematic. Some people who test, like the actress Angelina Jolie, learn information that can have dramatic consequences for their health and insurability—and that of their relatives.
And the testing business itself is still young and experiencing growing pains. Last month the Food and Drug Administration ordered genetic-testing firm 23andMe Inc. to stop marketing its $99 mail-order kit. The agency warned that false results could prompt consumers to undergo unnecessary health procedures. The company halted all ads for the kit and said it would work with regulators to address their concerns.
The entire article is here.